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Extracellular adenosine triphosphate (ATP) can activate purinergic receptors of the plasma
membrane and modulate multiple cellular functions. We report that ATP is released from
HIV-1 target cells through pannexin-1 channels upon interaction between the HIV-1
envelope protein and specific target cell receptors. Extracellular ATP then acts on purinergic receptors, including P2Y2, to activate proline-rich tyrosine kinase 2 (Pyk2) kinase and
transient plasma membrane depolarization, which in turn stimulate fusion between Envexpressing membranes and membranes containing CD4 plus appropriate chemokine coreceptors. Inhibition of any of the constituents of this cascade (pannexin-1, ATP, P2Y2, and
Pyk2) impairs the replication of HIV-1 mutant viruses that are resistant to conventional
antiretroviral agents. Altogether, our results reveal a novel signaling pathway involved in
the early steps of HIV-1 infection that may be targeted with new therapeutic approaches.

HIV-1 infection poses a public health problem
that is partially controlled by a combination of
specific antiretroviral agents. Nonetheless, the
surge of multiresistant HIV-1 strains will require

the development of novel antiviral strategies.Target
ing early infection by vaccines and microbicides
represents the main challenge to end the AIDS
epidemic (Haase, 2010;Virgin and Walker, 2010).
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A better understanding of the early steps of HIV-1 infection
is critical to achieving this goal. Enveloped viruses must fuse
their membranes with host cell membranes to allow productive infection. Major transient changes in the charge and
architecture of the host plasma membrane, including extreme
curvature, occur during early steps of infection and facilitate
viral replication (Miller et al., 1993; Davis et al., 2004). However, little is known about the consequences of these cell
membrane alterations on the early signaling pathway required
for viral infection.
Recent studies revealed that membrane stress induced by
mechanical or chemical stimuli (shear stress [Wan et al., 2008],
1824

osmotic swelling [Darby et al., 2003], and membrane shrinking [Corriden and Insel, 2010]) stimulates ATP release. Initially described as a second messenger in the nervous and
vascular systems (Schwiebert et al., 2002; Housley et al., 2009),
extracellular ATP may also act as a proinflammatory mediator
released during acute inflammation upon cell damage or bacterial infection, thus representing a generic marker of damage
which can alert the immune system to danger (Gallucci and
Matzinger, 2001). In addition, extracellular ATP inhibits infection by intracellular bacterial pathogens (Lammas et al.,
1997; Coutinho-Silva et al., 2003) and modulates immune
responses by participating in the chemotaxis of immune cells
ATP release boosts HIV-1 infectivity | Séror et al.
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Figure 1. ATP release through pannexin-1
hemichannels modulates interactions of
HIV-1 with target cells. (A) ATP released by
CD4+CXCR4+ cells during HIVNL43 infection
(MOI = 1; black circle) or in the absence of infection (white circle) was determined at different
time points by ATP-dependent bioluminescence in
three independent experiments. One representative experiment is shown (mean ± SEM of
triplicates; *, P < 0.01). (B) CD4+CXCR4+ cells
expressing a Tat-inducible -galactosidase
(-gal) reporter gene were infected with HIVNL43
(MOI = 1) during 48 h in the presence of different concentrations of apyrase. Then, the medium containing apyrase was removed, replaced
by complete medium, and target cell infection
was determined 48 h after infection (mean ± SEM;
three independent experiments; *, P < 0.05).
(C) ATP release was expressed as a fold
increase of ATP release during co-culture of
HIV-1 target cells with Env+ or Env cells. Error
bars indicate SEM of three independent determinations (*, P < 0.05). (D) Effect of ATP depletion by apyrase on HIV-1 envelope mediated
actin polymerization. Actin polymerization in
pairs of interacting cells was determined in
three independent experiments (means ± SEM;
*, P < 0.05) by fluorescence microscopy. The
inset illustrates actin polymerization (green)
between an Env+ cell (red) and an interacting
CD4+CXCR4+ cell (bar, 5 µm). (E) Localization of
pannexin-1 at the contact site between primary
HIV-1–infected lymphoblasts (green) and primary uninfected lymphoblasts, visualized by
confocal microscopy. The arrowhead points to
pannexin-1 accumulation (red) at the interface
between primary infected and uninfected lymphoblasts (bar, 5 µm). A representative micrograph with merged images of xz (bar, 4 µm) and yz (bar, 1 µm) optical sections are shown. (F) Polarization of pannexin-1 (red) on the virological synapse between HIV-1–infected lymphoblasts (blue) and that of HIV-1–infected
and uninfected cells. Arrowheads highlight the colocalization between pannexin-1 and the HIV-1 envelope glycoprotein gp41 (green; bar, 5 µm). The images in
E and F are representative of at least 40 cells in three independent experiments. (G) CEM cells were infected during 6 d with HIVNL43 (MOI = 1) in the presence of
different concentrations of DIDS or SITS. Effects on target cell survival and on p24 antigen release were determined. Error bars indicate SD of three independent
determinations (*, P < 0.01; **, P < 0.001). (H) CD4+CXCR4+ cells expressing Tat-inducible -gal reporter gene were infected with HIVNL43 (MOI = 1) during 3 h in
the presence of the indicated concentrations of the indicated inhibitors. The medium was removed, replaced by complete medium, and target cell infectivity
was determined (means ± SEM; n = 3; *, P < 0.01). (I) CD4+CXCR4+ cells were transfected during 48 h with siRNAs specific for pannexin-1 or control siRNA and
then infected with HIVNL43 (MOI = 1). Pannexin-1 mRNA expression was measured by quantitative real-time RT-PCR. The effect of pannexin-1 depletion on p24
antigen release was determined as described in Materials and methods (means ± SEM; n = 3; *, P < 0.01; **, P < 0.001). (J and K) Cells were transfected with
siRNA as in I. ATP release and HIV-1 infection were determined after 3 h (by ATP-dependent bioluminescence) and after 48 h (using CD4+CXCR4+ cells that
contain a Tat-inducible -Gal reporter), respectively. Results were obtained in three independent experiments (mean ± SEM; *, P < 0.05).
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RESULTS
ATP release from target cells participates in HIV-1 infection
Because membrane stress can induce the release of ATP from
mammalian cells (Corriden and Insel, 2010), we speculated that
HIV-1 infection might trigger ATP release from host cells. We
found that infection of human cells with X4-tropic HIV-1
(HIVNL43), which relies on the expression of CD4 and CXCR4
the receptor and co-receptor of HIV-1 (Dalgleish et al., 1984;
Feng et al., 1996), led to rapid ATP release within the first 2 h of
infection (Fig. 1 A). The depletion of CD4 by small interfering
RNAs (siRNAs) or the inhibition of CXCR4 with its antagonist AMD3100 prevented ATP release (Fig. S1, A, B, E, and F).
The addition of the nontoxic ATP-degrading enzyme apyrase
JEM Vol. 208, No. 9

Figure 2. Purinergic receptors modulate HIV-1 infection. (A–C) Effects of CXCR4 receptor antagonist AMD3100 and the general P2 receptor
antagonists suramin, PPADS, and OxATP on p24 release (A), host cell infectivity (B), and hemifusion/fusion (C), as observed during infection of
PHA+IL-2–stimulated human PBMCs with HIVNDK and HIVBaL (A), during
infection of CD4+CXCR4+ cells with HIVNL43WT and HIVNL43Env (B), or during
co-culture of Env+ cells with HIV-1 target cells (C). Columns in A–C show
means ± SEM (n = 3; *, P < 0.05). (D and E) Effects of 5 µM AMD3100,
10 UI/ml apyrase, 10 µM suramin, 100 µM PPADS, 100 µM OxATP, and
500 nM efavirenz (Efav) on viral RNA expression and on total viral DNA
expression of wild-type (HIVNL43WT) or VSVG pseudotyped (HIVNL43Env) HIV-1
in CD4+CXCR4+ cells. Viral RNA was detected by quantitative PCR. Note
that the internalization of pseudotyped HIVNL43Env virus was not reduced
by these inhibitors (D). Total viral DNA was determined by PCR and results
were normalized with respect to GAPDH (E). Efavirenz was used as an
internal control of reverse transcription activity inhibition. The results are
representative of three independent experiments.

(Fig. S1, A and D) prevented HIV-1 infection (Fig. 1 B), whereas
supplementation with ATP or with its nonhydrolyzable analogue
ATP-S did not enhance HIV-1 infection (Fig. S1, C and D),
perhaps because local ATP release is already optimal in the proximity of virions infecting cells. Co-culture of CD4+CXCR4+
cells with cells expressing the HIV-1 envelope glycoprotein com
plex (Env) at the plasma membrane also caused ATP release
1825
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(eosinophils, neutrophils, monocytes/macrophages, and immature DCs; Chen et al., 2006; Kronlage et al., 2010), by activating the NALP3 inflammasome (Mariathasan et al., 2006),
or by mediating costimulatory signals for antigenic stimulation (Schenk et al., 2008). Recent studies revealed that ATP
can also be released under basal conditions and influences a
large array of cellular responses. Thus, ATP seems to act as an
inside-out messenger that fine tunes signal transduction pathways (Corriden and Insel, 2010).
Outside of the cell, ATP acts as an autocrine/paracrine
signal, modulating a variety of cellular functions by activating
purinergic receptors (Corriden and Insel, 2010).These plasma
membrane–localized receptors belong to a larger family that
can be classified into ionotropic P2X receptor and metabotropic P2Y receptors (Ralevic and Burnstock, 1998). Metabotropic receptors are coupled to intracellular signaling pathways
through heterotrimeric G proteins (Abbracchio et al., 2006),
whereas ionotropic P2X receptors are associated with pores
that open upon ATP binding, allowing Ca2+ influx and K+
efflux (Ralevic and Burnstock, 1998). Seven members of
the P2X family (P2X1–7; Ralevic and Burnstock, 1998)
and eight P2Y receptors (P2Y1, P2Y2, P2Y4, P2Y6, P2Y11,
P2Y12, P2Y13, and P2Y14) have been characterized
(Abbracchio et al., 2003). Upon activation, these receptors,
which are widely distributed throughout the body, modulate
an array of cellular functions like plasma membrane perme
abilization, Ca2+ influx, and cell death (Surprenant and North,
2009). Purinergic receptors have been extensively involved in
the development of innate and/or adaptive immune responses
against pathogens (Lammas et al., 1997; Coutinho-Silva et al.,
2003; Chen et al., 2006; Mariathasan et al., 2006; Kronlage
et al., 2010) but have also been associated with chemotherapydriven anticancer immune responses (Ghiringhelli et al., 2009).
In this study, we determined whether ATP and purinergic
receptors might modulate HIV-1 infection.We found that the
HIV-encoded envelope glycoprotein complex (Env) can stim
ulate the release of ATP from HIV-1 target cells and that
extracellular ATP then stimulates purinergic signals that facili
tate HIV-1 infection.We characterized several elements of the
signal transduction pathway—which facilitates ATP release
from HIV-1 target cells and mediates autocrine ATP effects—
that are essential for the early steps of HIV-1 infection.

Published August 22, 2011

Figure 3. Detection of P2Y2 expression during HIV-1 infection.
(A–D) Immunohistochemical P2Y2 detection in lymph node biopsies
(A) and frontal cortex biopsies (B) obtained from HIV-1–infected patients.
The insets illustrate the absence of staining in lymph node and frontal
cortex biopsies from uninfected patients (bars, 50 µm). The percentage of
P2Y2+ cells was determined in lymph node (C) and frontal cortex (D) biopsies. Error bars represent means ± SEM (n = 5; *, P < 0.01). (E and F) P2Y2
detection in PBMCs obtained from uninfected or untreated HIV-1–infected
patients. Representative microphotographs are shown in E (bars, 20 µm)
and quantitative data are shown in F (mean ± SEM; n = 3; *, P < 0.05).
(G) Primary lymphoblasts were infected with HIVNDK (MOI=1) for the indicated periods. Then P2Y2 expression was evaluated by immunoblotting.
Representative immunoblots of three independent experiments are
shown. (H) Expression of P2Y2 on PBMC () and on PHA+IL-2–activated
PBMC was determined in three independent experiments and one representative immunoblot is shown.

as the cells were engaging in conjugates (Fig. 1 C). Apyrase
abolished conjugate formation and the accompanying actin
polymerization in juxtaposed cells (Fig. 1 D).The release of ATP
from cells constitutes a common response to shear stress and
osmotic imbalance (Wang et al., 2005) and can be mediated
through mechanosensitive pannexin-1 hemichannels (Bao et al.,
2004). Indeed, pannexin-1 was enriched at the contact site between HIV-1–infected lymphoblasts (which express Env on the
surface) and uninfected lymphoblasts (Fig. 1 E). Pannexin-1
polarization occurred in conditions in which the levels of
pannexin-1 protein remained constant (Fig. S1 G) and was preferentially detected in uninfected cells (Fig. S1, H and I). In addition, pannexin-1 was associated with virological synapses that
formed between infected and uninfected cells (Fig. 1 F).
1826

Purinergic receptors contribute to viral uptake
Extracellular ATP constitutes a common danger signal that is
sensed by distinct purinergic receptors (Khakh and North,
2006). General inhibitors of purinergic receptors, including
suramin, pyridoxal-phosphate-6-azophenyl-2,4-disulfonate
(PPADS), and oxidized ATP (OxATP), blocked the replication of both X4-tropic HIV (e.g., HIVNDK) and R5-tropic
HIV (e.g., HIVBaL) in activated T lymphoblasts (Fig. 2 A and
Fig. S2 A). Purinergic receptor antagonists also blocked the
replication of R5-tropic HIV-1 in macrophages (Fig. S2,
B and C) or DCs (Fig. S2, D and E) and that of clinical HIV-1
isolates in C8166 T leukemia cells (Fig. S2, F–H).
Cervical epithelial (HeLa) cells engineered to express
CD4/CXCR4, as well as a Tat-inducible -galactosidase
(-Gal) reporter, expressed -Gal upon infection with a lymphotropic HIV-1 (HIVNL43WT). Such cells also expressed
-Gal upon infection by an isogenic virus in which the
endogenous Env gene had been replaced by that of vesicular
stomatitis virus (VSV; HIVNL43Env) allowing the virus to
infect cells which lack CD4/CXCR4 (Reiser et al., 1996).
Purinergic receptor antagonists were more efficient in inhibiting -Gal induction by Env-expressing than that by VSVpseudotyped HIV-1 (Fig. 2 B and Fig. S3 A), indicating that
they mainly affect the receptor-dependent facet of HIV-1
infection. Purinergic receptor inhibition also reduced the hem
ifusion (which causes the exchange of fluorescent lipids between
interacting cells) and cell-to-cell fusion (syncytium formation
with mixture of the cytoplasm) between CD4+CXCR4+
cells and Env-expressing cells (Fig. 2 C and Fig. S3 B). Finally,
purinergic receptor antagonists prevented the entry of HIV-1
into cells, as revealed by their inhibitory effects on the detection
of HIV genomes at the RNA (Fig. 2 D) and DNA (Fig. 2 E)
levels within host cells. In contrast, purinergic receptor inhibition did not affect the replication of VSV-pseudotyped
ATP release boosts HIV-1 infectivity | Séror et al.
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Pharmacological inhibition of pannexin-1 with 4,4 diisothiocyanatostilbene-2,2-disulfonic acid (DIDS) or 4-acetamido4-isothiocyanatostilbene-2,2 disulfonic acid (SITS) protected
target cells against HIV-1–induced cell death (Fig. 1 G),
reduced p24 antigen release (Fig. 1 G), and inhibited HIV-1
infection and fusion between CD4/CXCR4 and Envexpressing cells (Fig. 1 H; and Fig. S1, J and K). In these 6-d-long
experiments, DIDS and SITS inhibited HIV-1 infection at
doses that are lower than those required to prevent fusion
between HIV Env+ and CD4+CXCR4+ cells, perhaps reflecting cumulative effects over multiple viral cycles and/or
distinct avidities (and hence susceptibilities to inhibition) of
the interaction of infectable cells with HIV-1 Env present at
the surface of cells versus viral particles. siRNA-mediated depletion of pannexin-1 from HIV-1 target cells also decreased
p24 antigen release (Fig. 1 I), reduced HIV-1 infection (Fig. 1 J),
blocked HIV-1 Env–mediated fusion (Fig. S1 L), and inhibited the release of ATP from host cells during conjugate formation (Fig. S1 L) and HIV-1 infection (Fig. 1 K). Thus,
extracellular ATP release plays a major role in Env-dependent
interactions between HIV-1 and host cells.

Published August 22, 2011
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HIV-1 (Fig. 2, D and E). These results demonstrate that purinergic receptors are critical for the Env-mediated internalization of HIV-1 into suitable target cells.
Purinergic receptor P2Y2 modulates
HIV-1 infection
To identify the principal purinergic receptors involved in
HIV-1 internalization, we determined purinergic receptor
expression on HIV-1 target cells (Fig. S4, A–N) and we selectively depleted the mRNAs coding for P2X1, P2X4, P2X7,
P2Y1, P2Y2, and P2Y6 by siRNAs (Fig. S5, A–F). Depletion
of P2Y2 consistently resulted in the strongest reduction in
JEM Vol. 208, No. 9

Env-triggered syncytium formation (Fig. S5 G). Immuno
reactive P2Y2 was detectable at higher levels in lymphoid
tissues (Fig. 3, A and C), in the frontal cortex (Fig. 3, B and D),
and in circulating leukocytes (Fig. 3, E and F) from untreated
HIV-1 carriers, as compared with uninfected carriers (Fig. 3, A,
B, and E) and samples stained with isotype control antibody
(Fig. S5, H and I). The levels of P2Y2 protein rapidly increased during in vitro HIV-1 infection of human PBMCs
(Fig. 3 G), or CD4+CXCR4+ HeLa cells (Fig. S5 J), as well as
after stimulation of human PBMCs with PHA and IL-2
(Fig. 3 H). Both HIV-1–infected and uninfected cells over
expressed P2Y2 (Fig. S6 A). Immunofluorescence microscopy
1827
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Figure 4. Role of P2Y2 in HIV-1 infection.
(A–D) Detection of P2Y2 (pink, A–C; red, D)
during the interaction between HIV-1–
infected lymphoblasts (green) and uninfected
lymphoblasts, as visualized by confocal microscopy. The inset in B represents a yz optical
section and shows the circular distribution of
P2Y2. Contrast phase in A and B revealed interacting lymphoblasts. 3D projection (C) and 3D
reconstruction (D) of merged images unraveled
a ring-like distribution of P2Y2 between interacting lymphoblasts (bars, 5 µm). (E) Detection
of P2Y2 on virological synapse mediated by
HIV-1 envelope between interacting lymphoblasts. Note the colocalization between P2Y2
(in red) and the HIV-1 envelope glycoprotein
gp41 (in green) between HIV-1–infected lymphoblasts (in blue) and uninfected lymphoblasts (arrowhead). Representative micrographs
of xy (bar, 5 µm), xz (bar, 4 µm), and yz (bar,
1 µm) optical sections are shown. Images in
A–E are representative of at least four independent experiments. (F) Frequency of P2Y2 polarization at the virological synapse induced by
HIV-1 between lymphoblasts. Data in F are
means ± SEM of three independent experiments (*, P < 0.05). (G) Lymphocytic T CEM cells
were infected during 6 d with HIVNL43 (MOI = 1)
in the presence of different concentrations of
the P2Y2 receptor antagonist kaempferol. Cell
survival and p24 release were measured.
Error bars indicate SD of three independent
determinations (*, P < 0.01; **, P < 0.001).
(H) CD4+CXCR4+ cells expressing Tat-inducible
-gal reporter gene were infected with HIVNL43
(MOI = 1) during 3 h in the presence of different kaempferol concentrations. 42 h after infection, the percentage of infected target cells was determined by -Gal detection (mean ± SEM; n = 3; **, P < 0.001).
(I) Effects of kaempferol on Env-induced hemifusion and fusion were determined after 24-h co-culture of CD4+CXCR4+ cells with Env+ cells (means ± SD;
n = 3; *, P < 0.01; **, P < 0.001). (J) Representative flow cytometric analysis of intracellular p24 antigen in HIVNDK-infected CEM cells previously transduced
with lentiviruses encoding indicated shRNA constructs. Representative profiles of three independent experiments are shown. (K) Cells were treated as in J and
intracellular p24 and p24 release into the supernatant were determined (mean ± SD; n = 3; *, P < 0.01). ND, not detectable. P2Y2 expression by shRNA-transduced clones was evaluated by immunoblotting (inset). (L) CD4+CXCR4+ cells expressing Tat-inducible -gal reporter gene were transfected during 48 h with
siRNAs specific for P2Y2 or control siRNA and infected with HIVNL43 (MOI = 1). Then, target cell infectivity was determined (means ± SD; n = 3; *, P < 0.01).
Insets show representative immunoblots of three independent experiments. (M) CD4+CXCR4+ cells were transfected with siRNA as in L. After 24 h of coculture with HIV-1 Env+ cells, hemifusion and fusion induced by HIV-1 envelope were determined (means ± SD; n = 3; *, P < 0.01). (N) CD4+CXCR4+ cells expressing Tat-inducible -gal reporter gene were transfected with the indicated siRNA and with the wild-type P2Y2 or the P2Y2/4A mutant. Cell fusion
mediated by the HIV-1 envelope was then evaluated by determining -Gal activity during co-culture with HIV-1 Env+ (mean ± SEM; n = 3; *, P < 0.01).

Published August 22, 2011

Figure 5. P2Y2 controls plasma membrane depolarization
during HIV-1 Env–mediated fusion. (A) Plasma membrane
depolarization of primary lymphoblasts 1 h after infection with
HIVNDK (MOI = 1) was determined by evaluating the increase of
fluorescence of DiBac4(3) probe by flow cytometry. Representative profiles of three independent experiments are shown.
(B) CD4+CXCR4+ cells were treated with 70 mM KCl or control
for 3 h. Plasma membrane depolarization was determined by
evaluating the increase of fluorescence of the DiBac4(3) probe.
Representative profiles of three independent experiments are
shown. (C) Frequency of plasma membrane depolarized
CD4+CXCR4+ cells after 3 h of 70 mM KCl treatment (mean ±
SEM; n = 3; *, P < 0.05). (D) Effects of 5 µM AMD3100 on HIV-1
Env–induced fusion in the absence or presence of 70 mM KCl.
The error bars represent means ± SEM (n = 3; *, P < 0.05).
(E) Effects of AMD3100, apyrase, PPADS, and OxATP on plasma
membrane depolarization after 1 h of HIVNDK infection. Results were obtained in three independent experiments (mean ± SEM; *, P < 0.05) using the
DiBac4(3) probe and flow cytometry. (F) Effects of transfections of human P2Y2 wild-type (P2Y2), P2Y2 mutant (P2Y2/4A) constructs, and siRNA against
P2Y2 (siRNA-1 P2Y2) on HIV-1 envelope–induced plasma membrane depolarization were determined as described in A (mean ± SEM; n = 3; *, P < 0.05).

P2Y2 triggers plasma membrane depolarization to allow
HIV-1 infection
Infection with HIV-1 is associated with a transient depolarization of the plasma membrane (Melikyan, 2008; Fig. 5 A).
Transient abolition of the plasma membrane K+ gradient by
culturing cells in a medium containing 70 mM KCl for 3 h
strongly induced membrane depolarization (Fig. 5, B and C)
and enhanced the fusion of Env+ and CD4+CXCR4+ cells
that was reduced in the presence of the CXCR4 antagonist
AMD3100 (Fig. 5 D), demonstrating that plasma membrane
depolarization of HIV-1 target cells is required for Envdependent fusion events. Plasma membrane depolarization
induced by HIV-1 infection was abolished by addition of
AMD3100, ATP-depleting apyrase, or several purinergic
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receptor antagonists (Fig. 5 E). To assess the involvement of
P2Y2 in this event, we transfected CD4+CXCR4+ with a
nonmutated P2Y2 cDNA (or as a control with the nonfunctional P2Y2/4A mutant) and observed that overexpression of
functional P2Y2 increased the plasma membrane depolarization
of CD4+CXCR4+ cells co-cultured with Env+ cells (Fig. 5 F).
Conversely, depletion of P2Y2 reduced HIV-1 Env–mediated
plasma membrane depolarization (Fig. 5 F). These results
demonstrate that the Src homology domain 3 binding sites
(PxxP) of P2Y2 (which is mutated in the carboxy-terminal
tail of P2Y2/4A) is required for plasma membrane depolarization and contributes to Env-dependent fusion events.
P2Y2-dependent activation of proline-rich tyrosine kinase 2
(Pyk2) is required for HIV-1 infection
P2Y2 (but not its mutant P2Y2/4A, see previous section)
participates in the formation of a polyprotein complex that
activates Pyk2 (Seye et al., 2004).We found that the activating
phosphorylation or autophosphorylation on tyrosine residue
402 of Pyk2 (Pyk2Y402*) increased after P2Y2 overexpression during infection of human PBMCs with HIV-1 (Fig. 6 A)
and during the formation of conjugates between Env+ and
CD4+CXCR4+ HeLa cells (Fig.S7 A). Pyk2Y402* overexpres
sion was mainly detected in HIV-1–infected cells (Fig. S7 B).
Moreover, Pyk2Y402* was enriched in ring-like structures at
the contact site between such conjugates (Fig. 6, B and D)
and between HIV-1–infected lymphoblasts and uninfected
lymphoblasts (Fig. 6, C and E). In addition, Pyk2Y402* polar
ization was preferentially observed in uninfected lymphoblasts (Fig. S7 C). The phosphorylation of Pyk2 was also
detectable in lymph nodes from untreated HIV-1 carriers
(Fig. 6, F and H), in the frontal cortex from patients with
HIV-associated encephalitis (HAE; Fig. 6, G and I), and in
circulating leukocytes from HIV-1 carriers, correlating with
viral load (Fig. 6 J). Approximately 40% of CD3+CD4, 60%
of CD4+, and 15% of CD19+ cells obtained from PBMCs revealed the activating phosphorylation of Pyk2 after in vitro
ATP release boosts HIV-1 infectivity | Séror et al.
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revealed the polarization of P2Y2 at the contact site between
HIV-1–infected and uninfected lymphoblasts (Fig. 4, A–F;
and Fig. S6, B–D). P2Y2 distributed to ring-like structures
(Fig. 4, B–E; and Fig. S6 E) that also contained the HIV-1
glycoprotein gp41 (Fig. 4 E) and the co-receptor CD4 (not
depicted), indicating that P2Y2 accumulated at the virological
synapse that is formed between HIV-1–infected and uninfected
lymphoblasts. This P2Y2 polarization was observed preferentially in uninfected cells (Fig. 4 F and Fig. S6 E). Pharmacological P2Y2 inhibition with kaempferol (Kaulich et al.,
2003; Fig. 4, G–I; and Fig. S6, F–H) or knockdown of P2Y2
(Fig. 4, J–M; and Fig. S6 I) reduced HIV-1–associated cell
death (Fig. 4 G), HIV-1 infection (Fig. 4, G–L), and Envmediated hemifusion and fusion (Fig. 4, I and M; and Fig. S6,
G and H), suggesting that P2Y2 controls HIV-1 infection.
Indeed, the transfection-enforced overexpression of P2Y2
increased the fusion between Env+ and CD4+CXCR4+ cells
(Fig. 4 N). In addition, the fusion-inhibitory effect of a P2Y2specific siRNA was overcome by transfection with a non
interferable P2Y2 cDNA but not with a nonfunctional P2Y2
mutant, P2Y2/4A (Seye et al., 2004), underscoring the contribution of this purinergic receptor to HIV-1 infection (Fig. 4 N).
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HIV-1 infection (Fig. S7 D). In addition, the vast majority of
syncytia detected in lymph nodes from untreated HIV-1 carriers or in the frontal cortex from patients with HAE were
positive for Pyk2Y402* (Fig. S7 E). Highly active antiretro
viral therapy reduced immunodetectable Pyk2Y402* in PBMC
from HIV-1–infected donors (Fig. 6 K). Depletion of P2Y2
reduced the phosphorylation of Pyk2 (Fig. S7 A) and inhibited the polarization of Pyk2Y402* at the contact sites between cocultured Env+ and CD4+CXCR4+ cells (Fig. 6 L) or
between HIV-1–infected and uninfected target cells (Fig. 6 M
and Fig. S7 F). Pyk2 depletion before HIV-1 infection similarly decreased intracellular p24 (Fig. 6, N and O; and Fig. S7 G)
JEM Vol. 208, No. 9

and p24 antigen release (Fig. 6 O), and Pyk2 knockdown
inhibited HIV-1 infection, as well as Env-mediated hemifusion
and fusion (Fig. 6 P). Collectively, these results indicate that
Pyk2 is a critical effector of HIV-1 infection, operating downstream of P2Y2.
Depletion of each of the protein components of the hypothetical cascade delineated in this paper (pannexin-1→
ATP→P2Y2→Pyk2) reduced infection by standard HIV-1
isolates (Fig. 1, B, I, and J; Fig. 4, J–L; and Fig. 6, N–P) as well
as by viruses that had been rendered resistant against reverse
transcription and integrase inhibitors by selective point mutations (Bacheler et al., 2000; Delelis et al., 2009; Fig. 7 A).
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Figure 6. P2Y2 induces Pyk2 activation
during HIV-1 infection. (A) PHA+IL-2–
stimulated human PBMCs were infected with
HIVNDK (MOI = 1) for the indicated periods.
Pyk2Y402* and Pyk2 expression were determined by immunoblotting. GAPDH expression
was used as loading control. Representative
immunoblots of three independent experiments are shown. (B) Representative
Pyk2Y402* polarization (red) between HIV
Env+ cells (green) and CD4+CXCR4+ cells was
analyzed by confocal microscopy (bar, 5 µm).
The inset in B shows the yz section (bar, 3
µm). (C) Detection of Pyk2Y402* (pink) polarization during interaction between HIV-1–
infected lymphoblasts (green) and uninfected
lymphoblasts by confocal microscopy (bar,
5 µm). The left inset represents an xz optical
section and polarization of Pyk2Y402* between interacting cells (bar, 4 µm). The right
inset corresponds to a yz optical section and
shows peripheral distribution of Pyk2Y402* in
the contact site within conjugates (bar, 3
µm). Images are representative of four independent experiments. (D and E) Frequency of
Pyk2Y402* polarization between single cells
and conjugates during co-culture of HIV Env+
cells and CD4+CXCR4+ cells (D) or co-culture
of HIV-1–infected lymphoblasts and uninfected lymphoblasts (E) was determined in
three independent experiments (mean ± SEM;
*, P < 0.05). (F–I) Detection of Pyk2Y402* in
lymph node sections (F and H) and frontal
cortex biopsies (G and I) obtained from HIV1–infected and uninfected patients (HIV-1–
infected bar, 50 µm; HIV-1 uninfected bar,
25 µm). The percentage of Pyk2Y402*+ cells found in lymph node (H) and frontal cortex biopsies (I) was quantified. Error bars represent means ± SEM (*, P < 0.01;
n = 5). (J) Correlation between Pyk2Y402* detected on PBMCs and viremia obtained from untreated HIV-1 carriers. The p-value corresponds to the
correlation coefficient. (K) Effect of HAART on Pyk2Y402* detected on PBMCs obtained from treated patients, as compared with untreated HIV-1–infected
donors (mean ± SEM; *, P = 0.0009). (L and M) Effects of P2Y2 knockdown on Pyk2Y402* polarization at the contact site between conjugates during
co-culture of HIV Env+ cells and CD4+CXCR4+ cells (L) or co-culture of HIV-1–infected T CEM cells and uninfected P2Y2-depleted T CEM cells (M), as
determined by confocal microscopy in three independent experiments (mean ± SEM; *, P < 0.01). (N and O) Effects of Pyk2 depletion on intracellular
p24 (N and O) and p24 antigen release (O), as determined by immunofluorescence staining and ELISA, respectively. The indicated parameters were measured after HIVNDK infection of CEM clones transduced with shRNAs specific for Pyk2, 6 d after infection. Representative FACS profiles of three independent experiments are shown in N and quantitative results (mean ± SD; n = 3; *, P < 0.01) are shown in O. (P) Effects of Pyk2 knockdowns on HIVNL43WT
infection, hemifusion, and fusion induced by HIV-1 envelope (mean ± SEM; n = 3; *, P < 0.05). The knockdown of Pyk2 by two nonoverlapping siRNAs
was confirmed by Western blot (inset).
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Similarly, purinergic receptor antagonists were able to inhibit
infection by genetically engineered therapy-resistant HIV-1
mutants (Fig. 7 B) and tritherapy-selected viruses (Fig. 7 C),
consistent with the possibility that inhibition of the pannexin-1→ATP→P2Y2→Pyk2 cascade can mediate antiretro
viral effects under conditions in which conventional therapy
fails. In addition, purinergic receptor antagonists reduced the
death of activated CD4+ T lymphoblasts infected by HIV-1
(Fig. 7 D), suggesting that interruption of P2Y2 signaling
confers immunoprotective effects.
DISCUSSION
Although many early steps of infectious processes are associated with host membrane alterations, there are no studies that
evaluate whether extracellular nucleotides might impact on
the viral life cycle. In this paper, we show that ATP is released
into the extracellular milieu during the early steps of HIV-1
infection and that this extracellular ATP is required for efficient viral uptake. During the initial stages of the infectious
process,ATP release may determine viral clearance or the persistence of the infection by effects on the immune system. Massive
ATP release during infection reportedly can deliver a danger
signal to immune effectors. Thus, extracellular ATP may activate the inflammasome, which participates in the caspase-1–
dependent maturation and secretion of the proinflammatory
cytokines IL-1, IL-18, and IL-33 (Schroder and Tschopp,
2010) or stimulate neutrophil migration and phagocytosis
(Chen et al., 2006). Moreover, extracellular ATP can favor the
killing of some intracellular pathogens (Lammas et al., 1997;
Coutinho-Silva et al., 2003) or, on the contrary, promote the
survival of other infectious agents (Corriden and Insel, 2010).
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Thus, a recent study revealed that OppA, the substratebinding domain of Mycoplasma hominis permease increases
the microbe’s extracellular survival by inducing release of
ATP from host cells (Hopfe and Henrich, 2008). In addition,
treatment of Mycobacterium avium–infected cells with apyrase
decreased intracellular survival of the pathogens (Woo et al.,
2007). Our results differ from these studies in that they demonstrate that extracellular ATP released by HIV-1 host cells
favors the initial steps of HIV-1 infection. Thus, ATP that is
rapidly released during the infectious process from HIV-1
target cells does not only act as a danger signal but also contributes to viral uptake.
In this paper, we report the identification of proteins involved in HIV-1–induced ATP release and in ATP-mediated
signaling events that contribute to viral infection. Thus, we
identified several novel proteins that are required for efficient
HIV-1 infection of CD4+ host cells and showed that HIV-1
can stimulate ATP release into the extracellular milieu through
pannexin-1 hemichannels, perhaps as a result of mechanical
stress of the host cell membrane (Bao et al., 2004). ATP then
acts in an autocrine and paracrine fashion to activate puri
nergic receptors, in particular P2Y2, a seven-transmembraneanchored G protein–coupled receptor that can induce the
phosphorylation/recruitment of the proline/tyrosine kinase
Pyk2 (Liu et al., 2004). Indeed, pannexin-1, P2Y2, and Pyk2
were all recruited to the contact site between Env-containing
and CD4/CXCR4-containing membranes, suggesting that
they act within the virological synapse to transduce signals
that enhance membrane-to-membrane fusion, participate in
the infectious process, and facilitate viral cell-to-cell transmission (Fig. 7 E; Jolly et al., 2007; Hübner et al., 2009).
ATP release boosts HIV-1 infectivity | Séror et al.
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Figure 7. Inhibition of pannexin-1,
P2Y2, and Pyk2 reduces HIV-1 infectivity
and T cell depletion associated with HIV-1
infection. (A) Effects of pannexin-1, P2Y2,
and Pyk2 siRNA on the infectious activity of
therapy-resistant HIV-1 mutated viruses
(HIVNL43RTK103N and HIVNL43IN140:148). Target cell
infectivity was determined using CD4+CXCR4+
cells expressing Tat-inducible -Gal reporter
gene. Results are representative of three independent experiments (mean ± SEM; *, P <
0.01). (B) Effects of different concentrations
of suramin, PPADS, and OxATP on HIV mutant
infectivity, as determined in A. (C) PH2+IL-2–
stimulated PBMCs obtained from HAARTtreated patients (with undetectable viremia)
were treated with 100 µM suramin, 100 µM
PPADS, and 100 µM OxATP. Then, p24 antigen
release was determined after 1, 3, and 7 d of
infection. Results shown are representative of
three HAART-treated patients. (D) HIVNDK-infected PHA+IL-2–stimulated lymphoblasts were treated with 5 µM AMD3100, 100 µM suramin, or 100 µM
PPADS. 7-AAD uptake (analyzed by flow cytometry) and intracellular p24 antigen expression (measured by flow cytometry) were assessed. Results were
pooled from three independent experiments (mean ± SEM; *, P < 0.01). (E) Involvement of pannexin-1, ATP release, P2Y2 activation, and Pyk2Y402*
phosphorylation in early stages of HIV-1 infection. Binding of HIV-1 envelope to cellular receptors leads to rapid ATP release from host cells through
pannexin-1. ATP then activates P2Y2 receptors, leading to activation (phosphorylation) of Pyk2 (Pyk2Y402*). P2Y2 and Pyk2 control plasma membrane
depolarization, hemifusion, and fusion, which are required for HIV-1 infection.

Published August 22, 2011

Ar ticle

JEM Vol. 208, No. 9

MATERIALS AND METHODS
Cells and culture conditions. PBMCs were isolated from the blood of
normal volunteers (Etablissement Français du Sang [EFS] Cabanel, Paris,
France) over a Ficoll-Hypaque density gradient. Blood was obtained through
the EFS in the setting of EFS-Institut Pasteur Convention. A written informed consent was obtained for each donor to use the cells for clinical research in compliance with French Law and the Biomedical Research
Committee Board from Institut Pasteur (Paris, France). CD14+ monocytes
were isolated from PBMC by positive selection using anti-CD14 beads
(Miltenyi Biotec). To generate monocyte-derived macrophages (MDMs),
purified monocytes were incubated in RPMI 1640 medium supplemented
with 100 U/ml penicillin–100 µg/ml streptomycin (Invitrogen) and 10%
FCS in the presence of 10 ng/ml recombinant human (rh) M-CSF (Pepro
Tech). After 6 d of culture, adherent cells corresponding to the macrophageenriched fraction were harvested, washed, and used for subsequent experiments. To generate monocyte-derived DCs (MDDCs), purified monocytes
were cultured in RPMI 1640 medium supplemented with 10% antibiotics
and FCS. Cultures were maintained for 6 d in 24-well trays (106 cells/well)
supplemented with 10 ng/ml rhGM-CSF (PeproTech) and rhIL-4 (PeproTech).
The medium was replaced every 2 d. After 6 d of culture, MDDCs
were semi-adherent cells and expressed high levels of DC-SIGN but not
monocyte/macrophage markers such as CD14 and CD16. Flow cytometry
analysis (CellQuest software; BD) demonstrated that MDMs and MDDCs
were >90% pure. T cells were subsequently prepared from the monocytedepleted cell fractions. PBLs were cultured for 48 h in fresh medium supplemented with 2.5 µg/ml PHA (Sigma-Aldrich) and 1 µg/ml rhIL-2 (PeproTech).
PBLs were then washed and cultured in growth medium containing 1 µg/ml
rhIL-2 for 24 h. These cells were infected with HIV-1 during 3 d with a
multiplicity of infection (MOI) of 1, as previously described (Saïdi et al.,
2008; Melki et al., 2010). HeLa cells stably transfected with the Env gene of
HIV-1 LAI/IIIB (HeLa Env) and HeLa cells transfected with CD4 (HeLa
CD4) were cultured alone or together at a 1:1 ratio in Dulbecco’s modified
Eagle’s medium supplemented with 10% FCS, 2 mM l-glutamine, and 100
UI/ml penicillin/streptomycin (Invitrogen) in the absence or in presence of
tested molecules. CEM T lymphocytes were maintained in RPMI 1640
medium containing 10% FCS, 2 mM l-glutamine, and 100 UI/ml penicillin/
streptomycin (Invitrogen).
Viral and pseudo-viral constructs. Viral stocks of wild-type X4, R5, and
resistant HIV-1 were obtained after transfection of 293T with virus encoding
plasmids as previously described (Perfettini et al., 2008; Delelis et al., 2009).
The standardization of HIV-1 infection was achieved by means of the Alliance HIV-1 P24 antigen ELISA assay (PerkinElmer) and infection of P4 cells
followed by fixation and determination of -galactosidase activity. Viral
RNA and DNA and viral production were analyzed, as previously described
(Delelis et al., 2009).
Pharmacological inhibitions. Primary human lymphoblasts, MDMs,
MDDCs, lymphocytic CEM cells, or CD4+CXCR4+ target cells were seeded
into 96-well culture plates (1–2 × 104 cells /well) and incubated 30 min with
increasing concentrations of apyrase, CXCR4 antagonist (AMD3100), the
P2 receptor antagonist suramin, the P2X-selective antagonist OxATP, the
P2Y-selective antagonist PPADS, carbenoxolone (CBX), DIDS, and SITS.
Then, cells were incubated with wild-type HIV-1,VSV-pseudotyped HIV-1,
therapy-resistant HIV-1 mutated viruses (1 ng of p24 antigen), or clinical HIV-1
isolates (15 ng of p24 antigen) for 3 h at 37°C in a 5% CO2 atmosphere. After
washing out unabsorbed virus, cells were cultured for the indicated times in
the presence of tested molecules. The absolute number of total remaining
viable cells and cell death were analyzed, as previously described (Lecoeur
et al., 2002; Melki et al., 2010). Apyrase, AMD3100, ATP, ATP-S, suramin,
PPADS, OxATP, CBX, DIDS, and SITS were purchased from Sigma-Aldrich.
RNA interference. siRNAs specific for pannexin-1 (siRNA-1, 5-GCUC
CAAGGUAUGAACAUA-3; siRNA-2, 5-ACGAUUUGAGCCUC
UACAA-3), CD4 (siRNA, 5-ACUGAGGAGUCUCUUGAUC-3),
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At present, the exact mechanisms by which P2Y2 modulates HIV-1 infection remain elusive. However, we found that
after the interaction between HIV-1 envelope and its coreceptors, P2Y2 was activated and could directly interact with
filamin A, a modulator of the actin cytoskeleton involved
in the formation of stable receptor–co-receptor complexes
(Jiménez-Baranda et al., 2007). P2Y2 can also indirectly,
through its SH3 binding (PxxP) site, control the phosphorylation of Pyk2 on tyrosine 402 (Liu et al., 2004), and this
event might induce its phosphorylation/relocation to the
virological synapse. Pyk2 regulates multiple signaling events
that participate in the reorganization of the actin cytoskeleton
and contribute to macrophage polarization and migration in
response to chemokine stimulation (Okigaki et al., 2003). Pyk2
can control HIV-1 Env–mediated fusion (Harmon and Ratner,
2008). During HIV-1 infection, Pyk2 is phosphorylated after
interactions between distinct Env variants (from X4- and
R5-tropic strains) and Env receptors on HIV-1 target cells
(CD4 and chemokine receptors; Davis et al., 1997). The
activating phosphorylation or autophosphorylation of Pyk2
(Pyk2Y402*) that we detected during HIV-1 infection in vitro
and in vivo might be induced in response to chemokine stimulation or elevations of intracellular Ca2+ concentrations (Lev
et al., 1995). Activated Pyk2 then may modulate the formation of a signaling complex that contains Src family kinases
and actin interacting proteins (Block et al., 2010). In this paper,
we identified the ATP-mediated stimulation of the purinergic receptor P2Y2 as an upstream event required for the
phosphorylation of Pyk2 (Pyk2Y402*). P2Y2 activation is
known to modulate Ca2+ influx after nucleotide binding
(Ralevic and Burnstock, 1998) and may also regulate Pyk2
activities by recruiting it into a polyprotein complex that also
contains the tyrosine kinase Src (Seye et al., 2004). Although
we demonstrated that P2Y2 activation induced Pyk2Y402*,
the precise mechanisms linking P2Y2 activation and polarization/phosphorylation of Pyk2 remain elusive. Moreover, future
investigations must explore how plasma membrane depolarization, which is essential for HIV-1 infection, results from
the activation of P2Y2 and Pyk2.
Inhibition of any of the constituents of the molecular cascade
that we delineated in this study (pannexin-1→ATP→P2Y2→
Pyk2) could interrupt the HIV-1 life cycle at the level of viral
entry. Thus, inhibition of pannexin hemichannels, enzymatic
depletion of extracellular ATP, antagonizing P2Y2 receptors, or
suppression of Pyk2 kinase activity could constitute effective
strategies for the blockade of HIV-1 infection, be it locally (for
instance by application of topical gels) or systemically (ideally
with orally available drugs). The toxicology of some putative
therapeutic agents acting on this cascade (such as apyrase) is satisfactory (Marcus et al., 2005), whereas that of others (such as suramin) is not (Grossman et al., 2001), underlining the need for the
development of highly specific inhibitors against pannexin-1,
P2Y2, and Pyk2. Beyond these clinical considerations, it will be
important to investigate whether any or all of the constituents of
the pannexin-1→ATP→P2Y2→Pyk2 pathway may participate
in host cell infection by HIV-1–unrelated viruses.
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Quantitative real-time RT-PCR. mRNA was isolated from cells after the
indicated treatments using the RNeasy kit (QIAGEN) according to the man
ufacturer’s instructions, and total RNA was converted into cDNA by standard reverse transcription with the TaqMan reverse transcription kit (Applied
Biosystems). Quantitative PCR were performed with the cDNA preparation
(1:50) in the Mx3000P system (Agilent Technologies) in a 25-µl final volume
with Brilliant QPCR Master Mix (Agilent Technologies). The primers for
human for human Panx-1 were 5-GGTGAGACAAGACCCAGAGC-3
(forward) and 5-GGCATCGGACCTTACACCTA-3 (reverse). The primers for human P2X1 were 5-GCTGGTGCGTAATAAGAAGGTG-3
(forward) and 5-ATGAGGCCGCTCGAGGTCTG-3 (reverse). The
primers for human P2X4 were 5-GATACCAGCTCAGGAGGAAAAC-3
(forward) and 5-GCATCATAAATGCACGACTTGAG-3 (reverse). The
primers for human P2X7 were 5-TGATAAAAGTCTTCGGGATCCGT-3
(forward) and 5-TGGACAAATCTGTGAAGTCCATC-3 (reverse). The
primers for human P2Y1 were 5-CTTGGTGCTGATTCTGGGCTG-3
(forward) and 5-GCTCGGGAGAGTCTCCTTCTG-3 (reverse). The
primers for human P2Y2 were 5-CCGCTCGCTGGACCTCAGCTG-3
(forward) and 5-CTCACTGCTGCCCAACACATC-3 (reverse). The
primers for human P2Y4 were 5-CGCTGCCCACCCTCATCTAC-3
(forward) and 5-CCGAGTGGTGTCATGGCACAG-3 (reverse). The
primers for human P2Y5 were 5-TGTTCAGTCTACCCACTCTCAG-3
(forward) and 5-CTTACTGCTGCCACTACTGAGC-3 (reverse). The
primers for human P2Y6 were 5-AACCTTGCTCTGGCTGACCTG-3
(forward) and 5-GCAGGCACTGGGTTGTCACG-3 (reverse). The primers for human P2Y8 were 5-CTCCTGGCGCACATCGTGAG-3
(forward) and 5-GGAGCGCACGGACGTGGTC-3 (reverse). The
primers for human P2Y10 were 5-GGTGTTCATGTGTGCTGCAGTC-3
(forward) and 5-ATGGCGGGATAGTTGGTCACG-3 (reverse). The
primers for human P2Y11 were 5-GAGGCCTGCATCAAGTGTCTG-3
(forward) and 5-ACGTTGAGCACCCGCATGATG-3 (reverse). The
primers for human P2Y12 were 5-ACCGGTCATACGTAAGAACGAG-3
(forward) and 5-GCAGAATTGGGGCACTTCAGC-3 (reverse). The
primers for human P2Y13 were 5-GGAAGCAACACCATCGTCTGTG-3
(forward) and 5-GACTGTGAGTATATGGAACTCTG-3 (reverse) and
for human GAPDH were 5-CAATGCATCCTGCACCACCAA-3 (forward) and 5-GTCATTGAGAGCAATGCCAGC-3 (reverse). Real-time
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PCR included initial denaturation at 95°C for 10 min, followed by 40 cycles
at 95°C for 30 s, 55°C for 1 min, and 72°C for 1 min, and one cycle at 95°C
for 1 min, 55°C for 30 s, and 95°C for 30 s. The CT values were normalized
to the housekeeping gene GAPDH.
Immunoblots, immunofluorescence, and flow cytometry. Total cellular
proteins were extracted in 250-mM NaCl-containing lysis buffer (250 mM
NaCl, 0.1% NP-40, 5 mM EDTA, 10 mM Na3VO4, 10 mM NaF, 5 mM
DTT, 3 mM Na4P2O7, and the protease inhibitor cocktail [EDTA-free protease inhibitor tablets; Roche]). 50 µg of protein extracts were run on 4–12%
SDS-PAGE and transferred at 4°C onto a nitrocellulose membrane. After
blocking, membranes were incubated with primary antibody at room temperature overnight. Horseradish peroxidase–conjugated goat anti–mouse or
anti–rabbit (SouthernBiotech) antibodies were then incubated for 1 h and
revealed with the enhanced ECL detection system. After 3 d of infection
with HIVNDK (MOI = 1), PHA/IL-2–stimulated peripheral blood lymphocytes were stained with 10 µM 5-chloromethylfluorescein diacetate (Cell
Tracker green; CMFDA; Invitrogen) and cocultured with uninfected lymphoblasts for 48 h. Cells were then fixed in 4% paraformaldehyde/PBS for
30 min, permeabilized in 0.1% SDS in PBS, and incubated with FCS for
20 min, as previously described (Perfettini et al., 2004). Polyclonal rabbit antibodies for the detection of P2Y2 were purchased from Abcam or Alomone
laboratories. Polyclonal rabbit antibodies against pannexin-1 were obtained
from Abcam and Millipore. The polyclonal rabbit antibodies used for the detection of Pyk2 and the phosphorylated form of Pyk2 on tyrosine 402
(Pyk2Y402*) were obtained from Cell Signaling Technology. The monoclonal mouse antibody against HIV-1 gp41 (50–69) was obtained from National
Institutes of Health AIDS Research and Reference Reagent Program (Bethesda,
MD). Antisera were used for immunodetection in PBS containing 1 mg/ml BSA
and revealed with goat anti–rabbit IgG conjugated to Alexa Fluor 546 fluorochromes from Invitrogen. Actin was also stained using an Alexa Fluor 647 (or
488)–conjugated phalloidin depending on the experiment. Cells were analyzed
by fluorescent confocal microscopy on an LSM510 (Carl Zeiss) using a 63×
objective. Z series of optical sections at 0.2-µm increments were acquired. After
image deconvolution, 3 D image reconstructions of interacting cells were
performed using the IsoSurface function of Imaris 5.7 Software (Bitplane AG).
Phenotypic analyses were realized by flow cytometry as previously described
(Melki et al., 2010), and we used the monoclonal mouse antibody against HIV-1
p24 (KC57) conjugated to FITC (Beckman Coulter), the monoclonal mouse anti
bodies against CD3 or CD4 conjugated to FITC or to peridinin chlorophyll
protein complex (PerCP; BD), and the monoclonal mouse antibody against
CD19 conjugated to allophycocyanin (Miltenyi Biotech).
Measurement of extracellular ATP. ATP release during co-cultures or
infection with HIV-1 were determined using the Enliten ATP assay system
(Promega) as described by the manufacturer. The luminescence was measured by integration over a 3-s time interval using the luminometer Fluostar
OPTIMA (BMG Labtech).
Hemifusion and cell–cell fusion assays. HeLa Env+ and HeLa CD4+CXCR4+
cells were, respectively stained for hemifusion analysis with 1 µM 1,1-dioctadecyl-3,3,3,3-tetramethylindocarbocyanine perchlorate (DiIC18(3), Invitrogen)
and 10 µM 5-chloromethylfluorescein diacetate (Cell Tracker green; CMFDA)
or for cell–cell fusion analysis, respectively, with 10 µM 5-chloromethylfluorescein diacetate (Cell Tracker green; CMFDA) and 10 µM 5-,6-,4-chloromethylbenzoyl aminotetramethyl rhodamine (Cell Tracker orange; CMTMR;
Invitrogen). Cells were then cultured alone or together for 24 h, at a 1:1 ratio
in Dulbecco’s modified Eagle’s medium supplemented with 10% FCS, 2 mM
l-glutamine, and penicillin/streptomycin (Invitrogen) in the absence or presence of the indicated concentrations of purinergic receptor inhibitors. The
effects of these inhibitors on hemifusion and cell–cell fusion mediated by the
HIV-1 envelope were evaluated by fluorescence microscopy.
Measurement of target cell infectability. HeLa cells stably transfected
with CD4, as well as the LacZ gene under the control of the HIV-1 LTR
(HeLa-CD4), were selected in medium containing 500 µg/ml G418. Target
ATP release boosts HIV-1 infectivity | Séror et al.
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P2X1 (siRNA, 5-GUGGCAGUCAGUAACCAUA-3), P2X4 (siRNA,
5-GGAAAACUCCCUCUUCGUC-3), P2X7 (siRNA, 5-GCUGUCGCUCCCAUAUUUA-3), P2Y1 (siRNA, 5-AUUAUCACCAGGUAAAUGGAUUUCC-3), P2Y2 (siRNA-1, 5-GGAUAGAAGAUGUGUUGGG-3;
siRNA-2, 5-GGCUGUAACUUAUACUAAA-3), P2Y6 (siRNA, 5-GG
UGCUCACAAAAAUACA-3), PYK2 (siRNA-1, 5-GCUGAUCGGCAUCAUUGAA-3; siRNA-2, 5-GGCGGUUCUUCAAGGAUAU-3), and
control sirRNA (5-GCCGGUAUGCCGGUUAAGU-3) were transfected 48 h before HIV-1 infection or cell fusion using Oligofectamine
(Invitrogen), according to the manufacturer’s instructions. For short hairpin RNA (shRNA) lentiviral particle transduction, the pRS shRNA expression retroviral vector coding for each targeted gene was purchased from
Origene. Oncovirus vector particles were generated by cotransfection of
three plasmids coding for the gag-pol genes from moloney mouse leukemia
virus (pUMVC3-gag-pol; University of Michigan), for the vector genome
carrying your shRNA of interest (pRS shRNA), and for the plasmid coding for an envelope of VSV (pMDG; Tronolab). Cotransfection was effected
into 293T cells (human embryonic kidney cell) using superFect transfection
reagent (QIAGEN) according to the manufacturer’s protocol.
On day 2 after transfection, supernatants were filtered (0.45-µm cellulose acetate filters; Sartorius Stedim), aliquoted, and frozen at 80°C. For
transduction, oncovirus aliquots were added to T lymphocytic CEM-T4 cell
line, and 24 h after infection the medium was replaced with fresh growth
medium containing 1 µg/ml puromycin (Cayla). Clonal populations were
obtained by transferring single cells into U-bottom 96-well plates and by
maintaining selection pressure for 3 wk. Silencing of proteins was determined by quantitative RT-PCR and/or by Western blotting.
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cell infectability was evaluated using HeLa-CD4+CXCR4+ cells. After 2 d of
infection, cells were lysed and -galactosidase activity was measured using
the enhanced -galactosidase assay kit (CPRG; Gene Therapy Systems).
Plasma membrane depolarization detection. PHA/IL-2–stimulated
human lymphoblasts were stained with 300 nM DiBac4(3) (Invitrogen) for
20 min at 37°C. Cells were then infected with HIVNDK (at an MOI of 1) for
1 h. We then measured the depolarization-associated increase of DiBac4(3)
fluorescence intensity by flow cytometry. Propidium iodide uptake was used
to exclude necrotic cells from the analysis of DiBac4(3) fluorescence. Using
the same procedure, we analyzed plasma membrane depolarization induced
by the HIV-1 envelope.

Immunohistochemical analysis. Biopsies from axillary lymph nodes and
from postmortem frontal cortex were obtained in accordance with the Italian
and EU legislations, after approval by the Institutional Review Board of the
National Institute for Infectious Disease Lazzaro Spallanzani. Human tissue
sections in paraffin were deparaffinized, rehydrated, and subjected to hightemperature antigen retrieval in 10 mM sodium citrate buffer, pH 6.0.
Endogenous peroxidase activity was blocked by 3% H2O2. Rabbit antibody
against P2Y2 (Alomone laboratories) or Pyk2Y402* (Abcam) and biotinylated goat anti–rabbit IgG were incubated with tissue sections. Immunoreaction product obtained with a preformed horseradish peroxidase–conjugated
streptavidin (Biogenex) was revealed using aminoethylcarbazole as chromogenic substrates and 0.01% H2O2 (Biogenex). Sections were then counterstained in Mayer’s acid hemalum. The lymph node and brain cortex sections
obtained from HIV-infected patients were evaluated by three independent
observers using a light microscope. For each slide, a minimum of 10 fields was
examined at 40× magnification.
Statistical analysis. To determine statistical significance, Student’s t test was
used for calculation of p-values.
Online supplemental material. Fig. S1 demonstrates pannexin-1–dependent
ATP release during HIV-1 infection and during HIV-1 Env–mediated fusion. Fig. S2 shows the impact of P2 inhibitors on cell viability, viral production, host cell infectivity, and hemifusion/fusion during HIV-1 infection. Fig. S3
shows effects of P2 inhibitors on co-cultured Env+ and CD4+CXCR4+
HeLa cells. Fig. S4 reveals purinergic receptor and pannexin-1 expression on human PBMCs and on PHA/IL-2–stimulated PBMC. Fig. S5
shows the identification of purinergic receptors involved in HIV-1 Env–
mediated fusion and controls for immunohistochemical analyses. Fig. S6 shows
the detection of polarized P2Y2 at the virological synapse mediated by HIVNDK.
Fig. S7 shows that Pyk2 is activated during HIV-1 infection. Online supplemental material is available at http://www.jem.org/cgi/content/full/jem
.20101805/DC1.
JEM Vol. 208, No. 9

Submitted: 31 August 2010
Accepted: 27 July 2011

REFERENCES

Abbracchio, M.P., J.M. Boeynaems, E.A. Barnard, J.L. Boyer, C. Kennedy,
M.T. Miras-Portugal, B.F. King, C. Gachet, K.A. Jacobson, G.A.Weisman,
and G. Burnstock. 2003. Characterization of the UDP-glucose receptor
(re-named here the P2Y14 receptor) adds diversity to the P2Y receptor family.
Trends Pharmacol. Sci. 24:52–55. doi:10.1016/S0165-6147(02)00038-X
Abbracchio, M.P., G. Burnstock, J.M. Boeynaems, E.A. Barnard, J.L. Boyer, C.
Kennedy, G.E. Knight, M. Fumagalli, C. Gachet, K.A. Jacobson, and G.A.
Weisman. 2006. International Union of Pharmacology LVIII: update
on the P2Y G protein-coupled nucleotide receptors: from molecular
mechanisms and pathophysiology to therapy. Pharmacol. Rev. 58:281–
341. doi:10.1124/pr.58.3.3
Bacheler, L.T., E.D. Anton, P. Kudish, D. Baker, J. Bunville, K. Krakowski,
L. Bolling, M. Aujay, X.V. Wang, D. Ellis, et al. 2000. Human immuno
deficiency virus type 1 mutations selected in patients failing efavirenz
combination therapy. Antimicrob. Agents Chemother. 44:2475–2484. doi:10
.1128/AAC.44.9.2475-2484.2000
Bao, L., S. Locovei, and G. Dahl. 2004. Pannexin membrane channels are
mechanosensitive conduits for ATP. FEBS Lett. 572:65–68. doi:10
.1016/j.febslet.2004.07.009
Block, E.R., M.A.Tolino, and J.K. Klarlund. 2010. Pyk2 activation triggers epidermal growth factor receptor signaling and cell motility after wounding
sheets of epithelial cells. J. Biol. Chem. 285:13372–13379. doi:10.1074/
jbc.M109.083089
Chen, Y., R. Corriden, Y. Inoue, L. Yip, N. Hashiguchi, A. Zinkernagel, V.
Nizet, P.A. Insel, and W.G. Junger. 2006. ATP release guides neutrophil
chemotaxis via P2Y2 and A3 receptors. Science. 314:1792–1795. doi:10
.1126/science.1132559
Corriden, R., and P.A. Insel. 2010. Basal release of ATP: an autocrine-paracrine
mechanism for cell regulation. Sci. Signal. 3:re1. doi:10.1126/scisignal
.3104re1
Coutinho-Silva, R., L. Stahl, M.N. Raymond, T. Jungas, P. Verbeke, G.
Burnstock, T. Darville, and D.M. Ojcius. 2003. Inhibition of chlamydial
infectious activity due to P2X7R-dependent phospholipase D activation. Immunity. 19:403–412. doi:10.1016/S1074-7613(03)00235-8
Dalgleish, A.G., P.C. Beverley, P.R. Clapham, D.H. Crawford, M.F. Greaves,
and R.A.Weiss. 1984.The CD4 (T4) antigen is an essential component of
the receptor for the AIDS retrovirus. Nature. 312:763–767. doi:10.1038/
312763a0
Darby, M., J.B. Kuzmiski, W. Panenka, D. Feighan, and B.A. MacVicar. 2003.
ATP released from astrocytes during swelling activates chloride channels.
J. Neurophysiol. 89:1870–1877. doi:10.1152/jn.00510.2002
Davis, C.B., I. Dikic, D. Unutmaz, C.M. Hill, J. Arthos, M.A. Siani, D.A.
Thompson, J. Schlessinger, and D.R. Littman. 1997. Signal transduction
due to HIV-1 envelope interactions with chemokine receptors CXCR4
or CCR5. J. Exp. Med. 186:1793–1798. doi:10.1084/jem.186.10.1793
Davis, H.E., M. Rosinski, J.R. Morgan, and M.L. Yarmush. 2004. Charged
polymers modulate retrovirus transduction via membrane charge neutralization and virus aggregation. Biophys. J. 86:1234–1242. doi:10.1016/
S0006-3495(04)74197-1
Delelis, O., I. Malet, L. Na, L. Tchertanov, V. Calvez, A.G. Marcelin, F. Subra,
E. Deprez, and J.F. Mouscadet. 2009. The G140S mutation in HIV integrases from raltegravir-resistant patients rescues catalytic defect due
1833

Downloaded from on April 17, 2017

Patients. Peripheral blood samples were obtained from healthy and HIV-1–
infected individuals (all males, mean age 36 yr) in accordance with the Italian
and EU legislations, after approval by the Institutional Review Board of the
National Institute for Infectious Disease Lazzaro Spallanzani. Patients were
naive for highly active antiretroviral therapy (HAART) with a plasma viral
load >20,000 copies/ml or were receiving HAART with a viral load <5,000
copies/ml. Plasma HIV-1 RNA levels were determined by the Abbott Realtime HIV-1 assay according to the manufacturer’s instructions (Abbott
Molecular). PBMCs of HIV-1–infected patients were obtained from residual samples intended to HIV RNA quantification for routine clinical
management and were isolated by Ficoll/Hypaque (GE Healthcare) centrifugation of heparinized blood from either healthy donors or HIV-seropositive individuals and fixed with 4% paraformaldehyde in PBS, pH 7.2.
PBMCs from HAART-treated patients that had undetectable virus in the
plasma were used for ex vivo experiments. The amounts of endogenous
virus produced and used during these ex vivo experiments were monitored
by using Vironostika HIV-1 Antigen assay according to the manufacturer’s
instructions (Biomerieux).

We thank the National Institutes of Health AIDS Research and Reference Reagent
Program (Bethesda, MD) and Laurie Erb (Bond Life Sciences Center, USA) for
reagents, and A. Jalil (Institut National de la Santé et de la Recherche Médicale
U753, France) and O. Duc (Institut Gustave Roussy, France) for technical help.
This work has been supported by a grant from Sidaction (to J.-L. Perfettini), as
well as grants from Agence Nationale des Recherches sur le Sida et sur les hépatites
virales, La Ligue Nationale contre le Cancer, Sidaction, and the European
Commission (RIGHT, ACTIVE P53, ApoSys, ArtForce; to G. Kroemer) and Istituto
Superiore di Sanità (no. 40F60, Ricerca Corrente e Finalizzate “Ministerio della
Saluté”, COFIN from Ministro dell’Istruzione, dell’Università e della Ricerca and
Associazione Italiana per la Ricerca sul Cancro).
The authors declare no conflicting financial interests.

Published August 22, 2011

1834

Mariathasan, S., D.S. Weiss, K. Newton, J. McBride, K. O’Rourke, M.
Roose-Girma, W.P. Lee, Y. Weinrauch, D.M. Monack, and V.M. Dixit.
2006. Cryopyrin activates the inflammasome in response to toxins
and ATP. Nature. 440:228–232. doi:10.1038/nature04515
Melikyan, G.B. 2008. Common principles and intermediates of viral proteinmediated fusion: the HIV-1 paradigm. Retrovirology. 5:111. doi:10.1186/
1742-4690-5-111
Melki, M.T., H. Saïdi, A. Dufour, J.C. Olivo-Marin, and M.L. Gougeon. 2010.
Escape of HIV-1-infected dendritic cells from TRAIL-mediated NK
cell cytotoxicity during NK-DC cross-talk—a pivotal role of HMGB1.
PLoS Pathog. 6:e1000862. doi:10.1371/journal.ppat.1000862
Miller, M.A., M.W. Cloyd, J. Liebmann, C.R. Rinaldo Jr., K.R. Islam, S.Z.
Wang,T.A. Mietzner, and R.C. Montelaro. 1993. Alterations in cell membrane permeability by the lentivirus lytic peptide (LLP-1) of HIV-1 transmembrane protein. Virology. 196:89–100. doi:10.1006/viro.1993.1457
Okigaki, M., C. Davis, M. Falasca, S. Harroch, D.P. Felsenfeld, M.P. Sheetz,
and J. Schlessinger. 2003. Pyk2 regulates multiple signaling events crucial
for macrophage morphology and migration. Proc. Natl. Acad. Sci. USA.
100:10740–10745. doi:10.1073/pnas.1834348100
Perfettini, J.L., T. Roumier, M. Castedo, N. Larochette, P. Boya, B. Raynal, V.
Lazar, F. Ciccosanti, R. Nardacci, J. Penninger, et al. 2004. NF-B and p53
are the dominant apoptosis-inducing transcription factors elicited by the
HIV-1 envelope. J. Exp. Med. 199:629–640. doi:10.1084/jem.20031216
Perfettini, J.L., R. Nardacci, M. Bourouba, F. Subra, L. Gros, C. Séror, G. Manic,
F. Rosselli, A. Amendola, P. Masdehors, et al. 2008. Critical involvement
of the ATM-dependent DNA damage response in the apoptotic demise
of HIV-1-elicited syncytia. PLoS ONE. 3:e2458. doi:10.1371/journal
.pone.0002458
Ralevic, V., and G. Burnstock. 1998. Receptors for purines and pyrimidines.
Pharmacol. Rev. 50:413–492.
Reiser, J., G. Harmison, S. Kluepfel-Stahl, R.O. Brady, S. Karlsson, and M.
Schubert. 1996. Transduction of nondividing cells using pseudotyped
defective high-titer HIV type 1 particles. Proc. Natl. Acad. Sci. USA. 93:
15266–15271. doi:10.1073/pnas.93.26.15266
Saïdi, H., M.T. Melki, and M.L. Gougeon. 2008. HMGB1-dependent
triggering of HIV-1 replication and persistence in dendritic cells as a
consequence of NK-DC cross-talk. PLoS ONE. 3:e3601. doi:10.1371/
journal.pone.0003601
Schenk, U., A.M. Westendorf, E. Radaelli, A. Casati, M. Ferro, M. Fumagalli,
C. Verderio, J. Buer, E. Scanziani, and F. Grassi. 2008. Purinergic control
of T cell activation by ATP released through pannexin-1 hemichannels.
Sci. Signal. 1:ra6. doi:10.1126/scisignal.1160583
Schroder, K., and J. Tschopp. 2010. The inflammasomes. Cell. 140:821–832.
doi:10.1016/j.cell.2010.01.040
Schwiebert, L.M.,W.C. Rice, B.A. Kudlow, A.L.Taylor, and E.M. Schwiebert.
2002. Extracellular ATP signaling and P2X nucleotide receptors in
monolayers of primary human vascular endothelial cells. Am. J. Physiol.
Cell Physiol. 282:C289–C301.
Seye, C.I., N. Yu, F.A. González, L. Erb, and G.A. Weisman. 2004. The P2Y2
nucleotide receptor mediates vascular cell adhesion molecule-1 expression through interaction with VEGF receptor-2 (KDR/Flk-1). J. Biol.
Chem. 279:35679–35686. doi:10.1074/jbc.M401799200
Surprenant, A., and R.A. North. 2009. Signaling at purinergic P2X receptors.
Annu. Rev. Physiol. 71:333–359. doi:10.1146/annurev.physiol.70.113006
.100630
Virgin, H.W., and B.D.Walker. 2010. Immunology and the elusive AIDS vaccine. Nature. 464:224–231. doi:10.1038/nature08898
Wan, J., W.D. Ristenpart, and H.A. Stone. 2008. Dynamics of shear-induced
ATP release from red blood cells. Proc. Natl. Acad. Sci. USA. 105:16432–
16437. doi:10.1073/pnas.0805779105
Wang, E.C., J.M. Lee, W.G. Ruiz, E.M. Balestreire, M. von Bodungen, S.
Barrick, D.A. Cockayne, L.A. Birder, and G. Apodaca. 2005. ATP and
purinergic receptor-dependent membrane traffic in bladder umbrella
cells. J. Clin. Invest. 115:2412–2422. doi:10.1172/JCI24086
Woo, S.R., R.G. Barletta, and C.J. Czuprynski. 2007. Extracellular ATP is
cytotoxic to mononuclear phagocytes but does not induce killing of
intracellular Mycobacterium avium subsp. paratuberculosis. Clin. Vaccine
Immunol. 14:1078–1083. doi:10.1128/CVI.00166-07
ATP release boosts HIV-1 infectivity | Séror et al.

Downloaded from on April 17, 2017

to the resistance Q148H mutation. Nucleic Acids Res. 37:1193–1201.
doi:10.1093/nar/gkn1050
Feng,Y., C.C. Broder, P.E. Kennedy, and E.A. Berger. 1996. HIV-1 entry cofactor:
functional cDNA cloning of a seven-transmembrane, G protein-coupled
receptor. Science. 272:872–877. doi:10.1126/science.272.5263.872
Gallucci, S., and P. Matzinger. 2001. Danger signals: SOS to the immune system.
Curr. Opin. Immunol. 13:114–119. doi:10.1016/S0952-7915(00)00191-6
Ghiringhelli, F., L. Apetoh, A.Tesniere, L. Aymeric,Y. Ma, C. Ortiz, K.Vermaelen,
T. Panaretakis, G. Mignot, E. Ullrich, et al. 2009. Activation of the NLRP3
inflammasome in dendritic cells induces IL-1beta-dependent adaptive immunity against tumors. Nat. Med. 15:1170–1178. doi:10.1038/nm.2028
Grossman, S.A., S. Phuphanich, G. Lesser, J. Rozental, L.B. Grochow, J. Fisher,
and S. Piantadosi; New Approaches to Brain Tumor Therapy CNS
Consortium. 2001. Toxicity, efficacy, and pharmacology of suramin in
adults with recurrent high-grade gliomas. J. Clin. Oncol. 19:3260–3266.
Haase, A.T. 2010. Targeting early infection to prevent HIV-1 mucosal transmission. Nature. 464:217–223. doi:10.1038/nature08757
Harmon, B., and L. Ratner. 2008. Induction of the Galpha(q) signaling cascade by the human immunodeficiency virus envelope is required for
virus entry. J.Virol. 82:9191–9205. doi:10.1128/JVI.00424-08
Hopfe, M., and B. Henrich. 2008. OppA, the ecto-ATPase of Mycoplasma
hominis induces ATP release and cell death in HeLa cells. BMC Microbiol.
8:55. doi:10.1186/1471-2180-8-55
Housley, G.D., A. Bringmann, and A. Reichenbach. 2009. Purinergic signaling
in special senses. Trends Neurosci. 32:128–141. doi:10.1016/j.tins.2009
.01.001
Hübner, W., G.P. McNerney, P. Chen, B.M. Dale, R.E. Gordon, F.Y. Chuang,
X.D. Li, D.M. Asmuth, T. Huser, and B.K. Chen. 2009. Quantitative
3D video microscopy of HIV transfer across T cell virological synapses.
Science. 323:1743–1747. doi:10.1126/science.1167525
Jiménez-Baranda, S., C. Gómez-Moutón, A. Rojas, L. Martínez-Prats, E.
Mira, R. Ana Lacalle, A.Valencia, D.S. Dimitrov, A.Viola, R. Delgado, et al.
2007. Filamin-A regulates actin-dependent clustering of HIV receptors.
Nat. Cell Biol. 9:838–846. doi:10.1038/ncb1610
Jolly, C., I. Mitar, and Q.J. Sattentau. 2007. Adhesion molecule interactions facilitate human immunodeficiency virus type 1-induced virological synapse formation between T cells. J. Virol. 81:13916–13921. doi:10.1128/
JVI.01585-07
Kaulich, M., F. Streicher, R. Mayer, I. Müller, and C.E. Müller. 2003.
Flavonoids — novel lead compounds for the development of P2Y2 receptor antagonists. Drug Dev. Res. 59:72–81. doi:10.1002/ddr.10203
Khakh, B.S., and R.A. North. 2006. P2X receptors as cell-surface ATP sensors
in health and disease. Nature. 442:527–532. doi:10.1038/nature04886
Kronlage, M., J. Song, L. Sorokin, K. Isfort, T. Schwerdtle, J. Leipziger, B.
Robaye, P.B. Conley, H.C. Kim, S. Sargin, et al. 2010. Autocrine purinergic receptor signaling is essential for macrophage chemotaxis. Sci. Signal.
3:ra55. doi:10.1126/scisignal.2000588
Lammas, D.A., C. Stober, C.J. Harvey, N. Kendrick, S. Panchalingam, and
D.S. Kumararatne. 1997. ATP-induced killing of mycobacteria by human
macrophages is mediated by purinergic P2Z(P2X7) receptors. Immunity.
7:433–444. doi:10.1016/S1074-7613(00)80364-7
Lecoeur, H., L.M. de Oliveira-Pinto, and M.L. Gougeon. 2002. Multiparametric
flow cytometric analysis of biochemical and functional events associated with apoptosis and oncosis using the 7-aminoactinomycin D assay.
J. Immunol. Methods. 265:81–96. doi:10.1016/S0022-1759(02)00072-8
Lev, S., H. Moreno, R. Martinez, P. Canoll, E. Peles, J.M. Musacchio, G.D.
Plowman, B. Rudy, and J. Schlessinger. 1995. Protein tyrosine kinase
PYK2 involved in Ca(2+)-induced regulation of ion channel and MAP
kinase functions. Nature. 376:737–745. doi:10.1038/376737a0
Liu, J., Z. Liao, J. Camden, K.D. Griffin, R.C. Garrad, L.I. Santiago-Pérez, F.A.
González, C.I. Seye, G.A. Weisman, and L. Erb. 2004. Src homology 3
binding sites in the P2Y2 nucleotide receptor interact with Src and regulate activities of Src, proline-rich tyrosine kinase 2, and growth factor
receptors. J. Biol. Chem. 279:8212–8218. doi:10.1074/jbc.M312230200
Marcus, A.J., M.J. Broekman, J.H. Drosopoulos, K.E. Olson, N. Islam, D.J.
Pinsky, and R. Levi. 2005. Role of CD39 (NTPDase-1) in thrombo
regulation, cerebroprotection, and cardioprotection. Semin. Thromb. Hemost.
31:234–246. doi:10.1055/s-2005-869528

